246 related articles for article (PubMed ID: 14740273)
1. Biochemical markers of types I and III collagen and limited joint mobility in type 1 diabetic patients.
Arkkila PE; Koskinen PJ; Kantola IM; Rönnemaa T; Seppänen E; Viikari JS
Acta Diabetol; 2003 Dec; 40(4):151-5. PubMed ID: 14740273
[TBL] [Abstract][Full Text] [Related]
2. Dupuytren's disease in type I diabetic subjects: investigation of biochemical markers of type III and I collagen.
Arkkila PE; Koskinen PJ; Kantola IM; Rönnemaa T; Seppänen E; Viikari JS
Clin Exp Rheumatol; 2000; 18(2):215-9. PubMed ID: 10812494
[TBL] [Abstract][Full Text] [Related]
3. Biochemical markers of type III and I collagen: association with retinopathy and neuropathy in type 1 diabetic subjects.
Arkkila PE; Rönnemaa T; Koskinen PJ; Kantola IM; Seppänen E; Viikari JS
Diabet Med; 2001 Oct; 18(10):816-21. PubMed ID: 11678972
[TBL] [Abstract][Full Text] [Related]
4. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
Kobayashi Y; Ochi M; Tokue A
Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bone resorption markers during hypocalcemia in dairy cows.
Liesegang A; Sassi ML; Risteli J; Eicher R; Wanner M; Riond JL
J Dairy Sci; 1998 Oct; 81(10):2614-22. PubMed ID: 9812267
[TBL] [Abstract][Full Text] [Related]
6. Limited joint mobility is associated with the presence but does not predict the development of microvascular complications in type 1 diabetes.
Arkkila PE; Kantola IM; Viikari JS; Rönnemaa T; Vähätalo MA
Diabet Med; 1996 Sep; 13(9):828-33. PubMed ID: 8891458
[TBL] [Abstract][Full Text] [Related]
7. [Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia].
Tanaka K; Shiraishi K; Sakamoto A; Jojima H; Masuchi K; Okubo Y; Tanaka M; Fuzimatsu Y; Fukahori S; Osabe S; Imamura Y; Honda J; Oizumi K
Rinsho Ketsueki; 1998 Apr; 39(4):273-80. PubMed ID: 9597894
[TBL] [Abstract][Full Text] [Related]
8. Collagen markers in peritoneal dialysis patients.
Graff J; Joffe P; Fugleberg S; Jensen LT
Adv Perit Dial; 1995; 11():24-7. PubMed ID: 8534714
[TBL] [Abstract][Full Text] [Related]
9. Bone marker alterations in patients with type 1 Gaucher disease.
Ciana G; Martini C; Leopaldi A; Tamaro G; Katouzian F; Ronfani L; Bembi B
Calcif Tissue Int; 2003 Mar; 72(3):185-9. PubMed ID: 12522660
[TBL] [Abstract][Full Text] [Related]
10. Urinary amino-terminal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in renal transplant recipients.
Teppo AM; Törnroth T; Honkanen E; Grönhagen-Riska C
Transplantation; 2003 Jun; 75(12):2113-9. PubMed ID: 12829921
[TBL] [Abstract][Full Text] [Related]
11. A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis.
St Clair EW; Moak SA; Wilkinson WE; Sanders L; Lang T; Greenwald RA
J Rheumatol; 1998 Aug; 25(8):1472-9. PubMed ID: 9712086
[TBL] [Abstract][Full Text] [Related]
12. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
[TBL] [Abstract][Full Text] [Related]
13. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
14. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
Charni N; Juillet F; Garnero P
Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
[TBL] [Abstract][Full Text] [Related]
15. Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer.
Santala M; Simojoki M; Risteli J; Risteli L; Kauppila A
Clin Cancer Res; 1999 Dec; 5(12):4091-6. PubMed ID: 10632345
[TBL] [Abstract][Full Text] [Related]
16. Serum concentrations of laminin P1 and aminoterminal propeptide of type III procollagen in sickle cell disease.
Bolarin DM; Swerdlow P; Wallace AM; Littsey L
Haematologia (Budap); 1998; 29(1):51-8. PubMed ID: 9704258
[TBL] [Abstract][Full Text] [Related]
17. Diabetic retinopathy and its association with limited joint mobility.
Haitas B; Jones DB; Ting A; Turner RC
Horm Metab Res; 1986 Nov; 18(11):765-7. PubMed ID: 3792994
[TBL] [Abstract][Full Text] [Related]
18. [Collagen synthesis and heart failure].
Jiménez-Navarro MF; Gómez-Doblas JJ; Cabrera-Bueno F; Cruz-Ocaña E; Rodríguez-Bailón I; Ruiz-Galdón M; Morell M; Molero E; de Teresa-Galván E
Rev Esp Cardiol; 2005 Aug; 58(8):975-8. PubMed ID: 16053832
[TBL] [Abstract][Full Text] [Related]
19. Comparison of carboxyterminal telopeptide of type I collagen (ICTP) and CA 125 as predictors of prognosis in ovarian cancer.
Santala M; Risteli J; Kauppila A
Anticancer Res; 2004; 24(2C):1057-62. PubMed ID: 15154623
[TBL] [Abstract][Full Text] [Related]
20. Association of adiponectin with procollagen type I carboxyterminal propeptide in non-diabetic essential hypertension.
Tsai WC; Lin CC; Chen JY; Huang YY; Lee CH; Li WT; Weng CM; Chen JH
Blood Press; 2008; 17(4):233-8. PubMed ID: 18671144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
